Matrix to up Citalopram export target to Europe

 Lundbeck, the original innovator of anti-depressant drug Citalopram, also withdrew its allegations of forgery and perjury made against Matrix Laboratories and its directors and employees in the court proceedings.

 On the back of non-infringing process patent granted to it by the European regulatory authorities, Matrix has been exporting Citalopram bulk active for over a year to Europe.

 Last fiscal, Citalopram alone contributed about Rs 200 crore to the sales of Matrix, accounting for almost 50 per cent of its turnover.

 About 20 generic formulators, which captured about 30 per cent market share for the anti-depressant product in Europe, are buying Citalopram from Matrix Labs through AET, the original marketing authorisation holder of generic formulations containing Citalopram. Lagap Pharma is one among them.